Progyny (PGNY) Expected to Announce Earnings on Thursday

Progyny (NASDAQ:PGNY) is projected to post its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect the company to announce earnings of $0.37 per share and revenue of $299.2270 million for the quarter. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS.Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:45 PM ET.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.19 EPS for the quarter, missing the consensus estimate of $0.42 by ($0.23). Progyny had a return on equity of 10.69% and a net margin of 4.28%.The business had revenue of $332.87 million during the quarter, compared to analyst estimates of $315.70 million. During the same quarter last year, the firm posted $0.17 EPS. The company’s revenue was up 9.5% compared to the same quarter last year. On average, analysts expect Progyny to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Progyny Stock Performance

NASDAQ:PGNY opened at $18.57 on Wednesday. Progyny has a one year low of $13.39 and a one year high of $26.76. The business’s 50-day simple moving average is $21.13 and its 200 day simple moving average is $21.89. The stock has a market cap of $1.60 billion, a price-to-earnings ratio of 31.47, a price-to-earnings-growth ratio of 1.57 and a beta of 1.29.

Insider Activity at Progyny

In other Progyny news, Director Kevin K. Gordon sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $22.04, for a total transaction of $55,100.00. Following the sale, the director owned 12,501 shares in the company, valued at $275,522.04. This represents a 16.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Allison Swartz sold 2,398 shares of the company’s stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $22.96, for a total value of $55,058.08. Following the transaction, the executive vice president directly owned 79,697 shares of the company’s stock, valued at $1,829,843.12. This trade represents a 2.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 7,895 shares of company stock worth $179,311 in the last 90 days. 9.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Progyny

Several institutional investors have recently made changes to their positions in PGNY. Canada Pension Plan Investment Board bought a new position in shares of Progyny during the second quarter valued at approximately $77,000. Tower Research Capital LLC TRC grew its holdings in shares of Progyny by 203.5% during the second quarter. Tower Research Capital LLC TRC now owns 7,021 shares of the company’s stock valued at $154,000 after purchasing an additional 4,708 shares during the last quarter. Teza Capital Management LLC grew its holdings in shares of Progyny by 5.4% during the second quarter. Teza Capital Management LLC now owns 10,068 shares of the company’s stock valued at $221,000 after purchasing an additional 516 shares during the last quarter. Amundi grew its holdings in shares of Progyny by 103.8% during the first quarter. Amundi now owns 11,419 shares of the company’s stock valued at $264,000 after purchasing an additional 5,817 shares during the last quarter. Finally, Walleye Capital LLC grew its holdings in Progyny by 6.9% in the 2nd quarter. Walleye Capital LLC now owns 12,080 shares of the company’s stock worth $266,000 after buying an additional 780 shares in the last quarter. 94.93% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

PGNY has been the topic of several recent analyst reports. Wall Street Zen upgraded Progyny from a “hold” rating to a “buy” rating in a research note on Saturday, July 26th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $28.00 price target (up previously from $26.00) on shares of Progyny in a research note on Friday, August 8th. Canaccord Genuity Group boosted their price target on Progyny from $21.00 to $23.00 and gave the stock a “hold” rating in a research note on Wednesday, August 20th. Leerink Partnrs upgraded Progyny from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 8th. Finally, Raymond James Financial set a $28.00 price objective on Progyny in a research note on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $25.44.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.